Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer

Overview

Journal Horm Cancer

Date 2018 Jan 18

PMID 29340907

Citations 15

Authors

Jessica L Christenson

Jane B Trepel

Haythem Y Ali

Sunmin Lee

Joel R Eisner

Edwina S Baskin-Bey

Anthony D Elias

Jennifer K Richer

Affiliations

Soon will be listed here.

Abstract

The androgen receptor (AR) is a promising therapeutic target for a subset of triple-negative breast cancers (TNBCs) in which AR is expressed. However, the mechanistic action of AR and the degree to which primary and metastatic tumors depend on AR, both before and after conventional treatment, remain to be defined. We discuss preclinical and clinical data for AR+ TNBC, the difficulties in monitoring AR protein levels, new methods for determining AR status, the influence of AR on "stemness" in the context of TNBC, the role of combined inhibition of sex steroid production and AR, and the role of AR in regulation of the immune system. Although the exact role of AR in subsets of TNBC is still being characterized, new therapies that target AR and the production of androgens may provide additional options for patients with TNBC for whom chemotherapy is currently the sole treatment option.

Citing Articles

Beyond Triple-Negative: High Prevalence of Quadruple-Negative Breast Cancer in African Americans.

Oladeru O, Rajack F, Esnakula A, Naab T, Kanaan Y, Ricks-Santi L Biomedicines. 2024; 12(7).

PMID: 39062096 PMC: 11275194. DOI: 10.3390/biomedicines12071522.

AKR1C2 Promotes Metastasis and Regulates the Molecular Features of Luminal Androgen Receptor Subtype in Triple Negative Breast Cancer Cells.

Li S, Lee W, Heo W, Son H, Her Y, Kim J J Breast Cancer. 2023; 26(1):60-76.

PMID: 36762781 PMC: 9981988. DOI: 10.4048/jbc.2023.26.e1.

The POLR3G Subunit of Human RNA Polymerase III Regulates Tumorigenesis and Metastasis in Triple-Negative Breast Cancer.

Lautre W, Richard E, Feugeas J, Dumay-Odelot H, Teichmann M Cancers (Basel). 2022; 14(23).

PMID: 36497214 PMC: 9735567. DOI: 10.3390/cancers14235732.

Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer.

Madera S, Izzo F, Chervo M, Dupont A, Chiauzzi V, Bruni S Cell Death Dis. 2022; 13(5):447.

PMID: 35534460 PMC: 9084267. DOI: 10.1038/s41419-022-04855-0.

FOXA1: A Pioneer of Nuclear Receptor Action in Breast Cancer.

Seachrist D, Anstine L, Keri R Cancers (Basel). 2021; 13(20).

PMID: 34680352 PMC: 8533709. DOI: 10.3390/cancers13205205.

References

Viselli S, Reese K, Fan J, Kovacs W, Olsen N . Androgens alter B cell development in normal male mice. Cell Immunol. 1998; 182(2):99-104. DOI: 10.1006/cimm.1997.1227. View

Hadji P, Kauka A, Bauer T, Tams J, Hasenburg A, Kieback D . Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German substudy. Climacteric. 2012; 15(5):460-6. DOI: 10.3109/13697137.2011.647839. View

Gucalp A, Traina T . Androgen receptor-positive, triple-negative breast cancer. Cancer. 2017; 123(10):1686-1688. DOI: 10.1002/cncr.30683. View

DeNardo D, Brennan D, Rexhepaj E, Ruffell B, Shiao S, Madden S . Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011; 1(1):54-67. PMC: 3203524. DOI: 10.1158/2159-8274.CD-10-0028. View

Dent R, Trudeau M, Pritchard K, Hanna W, Kahn H, Sawka C . Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1):4429-34. DOI: 10.1158/1078-0432.CCR-06-3045. View

Harvell D, Spoelstra N, Singh M, McManaman J, Finlayson C, Phang T . Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. Breast Cancer Res Treat. 2008; 112(3):475-88. DOI: 10.1007/s10549-008-9897-4. View

Qi J, Yang Y, Zhu H, Wang J, Jia Y, Liu N . Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients. Breast Cancer (Auckl). 2012; 6:1-8. PMC: 3256731. DOI: 10.4137/BCBCR.S8323. View

Antonarakis E, Lu C, Wang H, Luber B, Nakazawa M, Roeser J . AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014; 371(11):1028-38. PMC: 4201502. DOI: 10.1056/NEJMoa1315815. View

Roden A, Moser M, Tri S, Mercader M, Kuntz S, Dong H . Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol. 2004; 173(10):6098-108. DOI: 10.4049/jimmunol.173.10.6098. View

10.

Ingle J, Kalari K, Buzdar A, Robson M, Goetz M, Desta Z . Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. Steroids. 2014; 99(Pt A):32-8. PMC: 4339673. DOI: 10.1016/j.steroids.2014.08.007. View

11.

Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D . Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005; 24(29):4660-71. DOI: 10.1038/sj.onc.1208561. View

12.

Lai J, Lai K, Zeng W, Chuang K, Altuwaijri S, Chang C . Androgen receptor influences on body defense system via modulation of innate and adaptive immune systems: lessons from conditional AR knockout mice. Am J Pathol. 2012; 181(5):1504-12. PMC: 3483803. DOI: 10.1016/j.ajpath.2012.07.008. View

13.

Canzoniero J, Park B . Use of cell free DNA in breast oncology. Biochim Biophys Acta. 2016; 1865(2):266-74. DOI: 10.1016/j.bbcan.2016.03.006. View

14.

Cochrane D, Bernales S, Jacobsen B, Cittelly D, Howe E, DAmato N . Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014; 16(1):R7. PMC: 3978822. DOI: 10.1186/bcr3599. View

15.

Feng J, Li L, Zhang N, Liu J, Zhang L, Gao H . Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms. Oncogene. 2016; 36(20):2775-2790. DOI: 10.1038/onc.2016.432. View

16.

Liu X, Ledet E, Li D, Dotiwala A, Steinberger A, Feibus A . A Whole Blood Assay for AR-V7 and AR in Patients with Prostate Cancer. J Urol. 2016; 196(6):1758-1763. PMC: 5161406. DOI: 10.1016/j.juro.2016.06.095. View

17.

Gallicchio L, MacDonald R, Wood B, Rushovich E, Helzlsouer K . Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy. Breast Cancer Res Treat. 2011; 130(2):569-77. DOI: 10.1007/s10549-011-1611-2. View

18.

Zhu M, Horbinski C, Garzotto M, Qian D, Beer T, Kyprianou N . Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010; 70(20):7992-8002. PMC: 2978028. DOI: 10.1158/0008-5472.CAN-10-0585. View

19.

Qu F, Xie W, Nakabayashi M, Zhang H, Jeong S, Wang X . Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer. Clin Cancer Res. 2016; 23(3):726-734. PMC: 5675562. DOI: 10.1158/1078-0432.CCR-16-1070. View

20.

Reyes E, VanderWeele D, Isikbay M, Duggan R, Campanile A, Stadler W . Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer. J Transl Med. 2014; 12:313. PMC: 4252013. DOI: 10.1186/s12967-014-0313-z. View